Build a career powered by innovations that matter! At Novanta, our innovations power technology products that are transforming healthcare and advanced manufacturing—improving productivity, enhancing people’s lives and redefining what’s possible. We create for our global customers engineered components and sub-systems that deliver extreme precision and performance for a range of mission-critical applications—from minimally invasive surgery to robotics to 3D metal printing.

Novanta is one global team with over 26 offices located in The Americas, Europe and Asia-Pacific. Looking for a great place to work? You have found it with a culture that embraces teamwork, collaboration and empowerment. Come explore Novanta.

Business Unit Overview
This position is part of Novanta’s Celera Motion business unit. Derived from the Latin word “celer” for quick and swift, the name Celera reflects our commitment to delivering motion control solutions that accelerate our customers’ ability to deliver innovative solutions to their markets. Celera Motion’s cohesive vision, superior technologies, consultative team approach and best-in-class reliability make us the trusted partner in solving the most challenging motion control problems. Celera Motion’s precision component and subsystem solutions solve application-specific challenges for technology-driven original equipment manufacturers from a range of markets.

Summary
We are looking for a talented, and highly motivated junior engineer who will be responsible for bringing new products to market reality whilst ensuring high levels of quality to current products. Come join a team of deeply knowledgeable engineers that strive to build the most robust and reliable motion control systems using cutting-edge development tools and practices. The engineer selected will assist in defining, performing and interpreting tests for products and components. You'll apply testing procedures to ensure product quality and reliability.

Primary Responsibilities

You'll collaborate with cross-functional teams to identify and troubleshoot issues, ensuring high-quality product standards are met.
Collaborating with development teams to understand product requirements and create comprehensive test plans.
Executing test cases, documenting results, and communicating findings to stakeholders.
Identifying and troubleshooting issues to provide detailed defect reports and support resolution efforts.
Contributing to the improvement of testing processes and procedures to enhance overall product quality.
Participating in the review and analysis of system specifications to ensure testability and identify potential risks Engineering effectiveness Quality of test procedures.

Required Experience, Education, Skills, Training and Competencies

Bachelor's degree in engineering or related field with basic understanding of engineering concepts and principles.
Basic understanding of product development lifecycle, testing best practices, and test automation tools.
Demonstrate good problem analytical, problem solving, and communication skills.
Experience with electronic circuit technology design and assembly processes.
Fluent in written and spoken Spanish and English.
Personal interest in the Robotics/Motion Control field.
Ability to work in a team-oriented, collaborative environment.
Positive, proactive, and energetic attitude.
High attention to detail with a desire for excellence.

Novanta is proud to be an equal employment opportunity and affirmative action workplace. We consider all qualified applicants without regard to race, color, religion, sex (including pregnancy), sexual orientation, gender identity or expression, national origin, military and veteran status, disability, genetics, or any other category protected by federal law or Novanta policy.

Please call +1 781-266-5700 if you need a disability accommodation for any part of the employment process.

About the company

Novanta designs and supplies core technology platforms for precision photonics used in medical devices and advanced industrial equipment. Its products are components and subsystems—such as lasers, optics, sensors, and imaging hardware—that OEMs integrate into their own machines. Unlike companies that sell end-user devices, Novanta focuses on providing the underlying photonics technology that OEMs build into products, enabling reliable performance and scalable manufacturing. The company differentiates itself through deep specialization in photonics and by growing through acquisitions, aligning its portfolio toward medical technology and precision industrial markets. Its goal is steady, long‑term growth by delivering proven core technologies that help customers develop better medical devices and industrial solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bedford, Massachusetts

Founded

1968

Get referred to Novanta

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue reached $265.8 million; organic growth hit 9.3%.
August 5, 2026 guidance lifted full-year revenue to $1.13-1.14 billion.
August 19, 2026 FUSIONultra launched for life-science imaging, sequencing, and flow cytometry.

What critics are saying

July 2026 Syracuse WARN notice cut 49 jobs, signaling ongoing manufacturing consolidation.
Riverpoint integration threatens margins and EPS if OEM customers reject pricing or synergies slip.
A failed Riverpoint integration and OEM design-loss cycle would collapse Novanta's growth story.

What makes Novanta unique

Novanta sells proprietary sub-systems, not commodity parts, across medical and industrial OEMs.
Riverpoint Medical doubled recurring surgical consumables and pushed medical exposure to 60% revenue.
FUSIONultra bundles ULTRALOQ, multi-wavelength lasers, and modular optics for OEM integration.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Performance Bonus

Company News

Financial Post

Aug 28th, 2026

Novanta to present at Baird Global Healthcare Conference on Tuesday, September 15, 2026.

Novanta to present at Baird Global Healthcare Conference on Tuesday, September 15, 2026. Business Wire Published Aug 28, 2026 BOSTON - Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta's common shares are quoted on Nasdaq under the ticker symbol "NOVT." More information about Novanta is available on the Company's website at www.novanta.com. For additional information, please contact Novanta Inc. Investor Relations at (781) 266-5137 or [email protected]. View source version on businesswire.com: Novanta Inc. Investor Relations Contact: (781) 266-5137 This advertisement has not loaded yet. Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Conversation | All Comments Start the conversation Advertisement Powered by Featured Local Savings

Packworld

Aug 27th, 2026

Configurable light engine platform.

Configurable light engine platform. Novanta introduces FUSIONultra: Designed for advanced life science instruments, the new multi-wavelength laser light engine combines stability, power control, and modularity to help OEMs accelerate innovation and improve imaging performance. Aug 27, 2026 This content was written and submitted by the supplier. It has only been modified to comply with this publication's space and style. Novanta, a trusted technology partner to leading OEMs in the life sciences and advanced technology markets, announced the availability of FUSIONultra, a configurable multi-wavelength laser light engine platform engineered to deliver stable, high-performance illumination for advanced imaging, analytical, and bioinstrumentation systems. FUSIONultra combines high power, ultra-stable operation, precise modulation, and flexible configuration options in a single OEM-ready platform designed to simplify integration while advancing instrument performance. As life science applications continue to demand higher throughput, greater sensitivity, and more reliable data, illumination performance has become a key determinant of instrument analytical performance, throughput, and data quality. Researchers increasingly rely on advanced fluorescence imaging and analytical systems to generate the high-quality data needed to accelerate scientific discovery, improve diagnostics, and support the development of next-generation therapies. FUSIONultra addresses these challenges through a modular architecture that enables OEMs to tailor wavelength combinations, power levels, beam delivery, and integrated optical features to meet specific application requirements. "Today's life science innovators need more than a light source. They need an illumination platform that enables better data quality, faster acquisition speeds, and greater confidence in system performance," said Konstantinos Sarglou, Director of Product Line Management. "FUSIONultra was designed to transform illumination from a supporting component into a competitive advantage, helping OEMs accelerate development while delivering the performance their customers demand." Built around Novanta's proprietary ULTRALOQ(TM) technology, FUSIONultra maintains exceptional laser stability across changing environmental conditions, reducing drift, minimizing downtime, and ensuring reliable operation over the lifetime of the instrument. The platform integrates both high-performance DPSS and diode laser technologies within a configurable architecture that can support multiple laser lines, enabling customers to optimize performance for a wide range of fluorescence imaging and analytical applications. Key features include: - Configurable multi-wavelength architecture supporting a broad range of laser combinations - Ultra-stable laser performance enabled by proprietary ULTRALOQ(TM) technology - High dynamic range excitation for precise control across demanding imaging workflows - Integrated variable optical attenuation for consistent performance across power levels - Optional beam shaping and despeckling technologies to improve illumination uniformity and reduce imaging artifacts - Single-mode and multi-mode output configurations to support diverse instrument requirements - Fast modulation capabilities that enable high-speed acquisition and testing workflows Novanta's FUSIONultra is purpose-built for OEM integration across a growing range of life science applications, including fluorescence imaging, spatial biology, DNA sequencing, flow cytometry, super-resolution microscopy, single-cell analysis, and advanced bioanalytical systems. By combining multiple advanced photonics technologies into a single platform, Novanta helps customers reduce integration complexity while accelerating time-to-market. The introduction of FUSIONultra reflects Novanta's broader commitment to advancing precision photonics solutions that enable breakthrough scientific discovery and innovation. As a vertically integrated provider of laser sources, beam delivery technologies, and sub-systems, Novanta offers machine builders a unique ability to streamline development and optimize system-level performance. Companies in this product You're Invited!

Informa TechTarget

Aug 18th, 2026

Experts call FCC's block on foreign robotics a nearshoring tactic.

Experts call FCC's block on foreign robotics a nearshoring tactic. While cyberthreats are a growing risk to national security, the agency's sweeping block on humanoids, quadrupeds and mobile robot imports could reinvigorate domestic suppliers. Published Aug. 18, 2026 First published on Following the Trump administration's move last month to block the sale of advanced industrial robots from all countries outside of the United States, experts are mixed on the outcome but ultimately supportive of what this could mean from a supply standpoint. The Federal Communications Commission on July 28 updated its covered list to include imports of mobile robots, such as humanoids and quadrupeds, as well as connected power inverters, citing national security risks. Products meeting those definitions can no longer receive FCC equipment authorization and cannot be imported, marketed or sold in the U.S., making them essentially banned. Affected companies can apply for a conditional approval. The sweeping action, which immediately took effect, came amid growing concern over China's ability to surveil customers and obtain sensitive data around the world from devices assembled in the country. However, it also looks to address another issue entirely - the U.S. falling behind globally in terms of robot production and deployment. "Domestically, we need help," Robert Little, a business development advisor and former chief of robotics strategy at Novanta, said. At first glance, Little said he thought the move was necessary for cybersecurity reasons. But after looking at the FCC's similar action regarding drones and drone parts, he said the recent ban was also a mechanism to drive domestic production of humanoids and mobile robots, as well as incentive for foreign suppliers to build their supply chains in the U.S. "That's its ultimate purpose," Little said. "And I think it can be effective." The U.S. is considered one of the global robotics leaders when it comes to investor capital, fueled by surging interest in AI, foundation model research and robotics systems. U.S.-headquartered companies such as Figure AI, Agility Robotics and Tesla received 52% of the $9.4 billion in global venture capital deployed last year, according to the Robotics Center of Silicon Valley. However, there is a widening gap between the number of robots manufactured by U.S. companies versus Chinese competitors. China installed 295,000 robots in 2024, representing more than half of the world's market share, according to the International Federation of Robotics. While preliminary 2025 numbers have not been released yet for China, the group estimated that installations are about ten times higher than the U.S. In other words, the "U.S. leads the world in where robotics is heading...while losing the race on where robotics is shipping today," the Robotics Center of Silicon Valley said in its 2026 report. To address the issue, the Association for Advancing Automation has urged Congress to consider adopting a national robotics strategy that includes subsidies, tax incentives and other means to drive domestic adoption and production of U.S. robots. The FCC's move, which only applies to new products, creates a runway for domestic companies to become more competitive, Little said. Then if the restrictions are lifted in the next few years, "they'll be in a much better place." Erik Nieves, founder and CEO of Plus One Robotics, said he knew the Trump administration would put restrictions on China's robots but was surprised by the breadth of the FCC's ban. Rather than just targeting China, the move affected robotics from all other countries, including trade partners such as Japan, Germany and South Korea. "We would have preferred to see it be more circumspect, but you don't control what the government does," Nieves said. "If it's true that every action is an overreaction, that's what this is." He also pointed out that the impact of the ban depends on the complexity of the conditional approval from the U.S. Department of Defense. Nieves said the details are unclear about the exemption process, adding that if it's more than just a simple check, then the U.S. could be "excessively hampering partners that we really would not rather do that to." Some say the ban doesn't go far enough. In a recent LinkedIn post, Standard Bots CEO Evan Beard said that fixed industrial robot arms should be part of the FCC's covered list because, similar to mobile robots, they have a networked, sensing, actuated system and raise security risks.

Yahoo Finance

Aug 14th, 2026

Novanta beats Q2 estimates, raises full-year revenue guidance to $1.14B

Novanta reported second-quarter revenue of $265.8 million, beating analyst estimates of $262.3 million with 10.3% year-on-year growth. The medical technology company also exceeded expectations on adjusted earnings per share ($0.89 versus $0.83 estimated) and adjusted EBITDA ($60.73 million versus $58.88 million estimated). CEO Matthijs Glastra attributed the performance to organic growth across all business units, driven by increased demand in precision robotics, AI-driven manufacturing, and minimally invasive surgery. New product revenue jumped more than 50% year-on-year. The company raised its full-year revenue guidance to $1.14 billion at the midpoint from $1.05 billion, an 8.4% increase. Management also lifted adjusted earnings guidance to $3.71 per share at the midpoint. During the earnings call, analysts questioned humanoid robotics deployments, Gen AI data centre exposure, and core gross margin evolution.

Yahoo Finance

Aug 7th, 2026

Novanta raises outlook to $1.14B revenue after Riverpoint acquisition doubles medical consumables to $300M

Novanta reported strong second-quarter results with 9% organic sales growth, 16% adjusted EBITDA increase, and 17% adjusted earnings per share growth. Adjusted gross margin expanded to 47%, whilst operating cash flow reached $65 million, bringing year-to-date cash flow to $117 million. The Automation Enabling Technologies segment led growth with 12% higher revenue and 18% bookings increase. Generative AI-related applications represented approximately 17% of revenue and grew roughly 25%. The company also received its first major servo-drive orders for humanoid robot development. Following the Riverpoint Medical acquisition closure, Novanta raised its 2026 outlook. The company now expects revenue of $1.13 billion–$1.14 billion, adjusted EBITDA of $273 million–$278 million, and adjusted EPS of $3.68–$3.74.

Novanta

Junior Test Engineer

About the job